BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 28527063)

  • 1. The role of anti-CGRP antibodies in the pathophysiology of primary headaches.
    Barbanti P; Aurilia C; Fofi L; Egeo G; Ferroni P
    Neurol Sci; 2017 May; 38(Suppl 1):31-35. PubMed ID: 28527063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data.
    Khan S; Olesen A; Ashina M
    Cephalalgia; 2019 Mar; 39(3):374-389. PubMed ID: 29110503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review.
    Schuster NM; Rapoport AM
    Clin Neuropharmacol; 2017; 40(4):169-174. PubMed ID: 28644160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitonin gene-related peptide antagonism and cluster headache: an emerging new treatment.
    Ashina H; Newman L; Ashina S
    Neurol Sci; 2017 Dec; 38(12):2089-2093. PubMed ID: 28856479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
    Yuan H; Spare NM; Silberstein SD
    Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine.
    Israel H; Neeb L; Reuter U
    Curr Pain Headache Rep; 2018 Apr; 22(5):38. PubMed ID: 29623520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Migraine and cluster headache - the common link.
    Vollesen AL; Benemei S; Cortese F; Labastida-Ramírez A; Marchese F; Pellesi L; Romoli M; Ashina M; Lampl C;
    J Headache Pain; 2018 Sep; 19(1):89. PubMed ID: 30242519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date.
    Pellesi L; Guerzoni S; Pini LA
    Clin Pharmacol Drug Dev; 2017 Nov; 6(6):534-547. PubMed ID: 28409893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CGRP pathway monoclonal antibodies for cluster headache.
    Chan C; Goadsby PJ
    Expert Opin Biol Ther; 2020 Aug; 20(8):947-953. PubMed ID: 32241175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.
    Bigal ME; Walter S; Rapoport AM
    Headache; 2013 Sep; 53(8):1230-44. PubMed ID: 23848260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CGRP Monoclonal Antibodies for Migraine: Rationale and Progress.
    Yuan H; Lauritsen CG; Kaiser EA; Silberstein SD
    BioDrugs; 2017 Dec; 31(6):487-501. PubMed ID: 29116598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.
    Bigal ME; Walter S
    CNS Drugs; 2014 May; 28(5):389-99. PubMed ID: 24638916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erenumab in the treatment of migraine.
    Jain S; Yuan H; Spare N; Silberstein SD
    Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
    Tringali G; Navarra P
    Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy.
    Raffaelli B; Reuter U
    Neurotherapeutics; 2018 Apr; 15(2):324-335. PubMed ID: 29616494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CGRP in human models of primary headaches.
    Ashina H; Schytz HW; Ashina M
    Cephalalgia; 2018 Feb; 38(2):353-360. PubMed ID: 27940880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CGRP monoclonal antibodies in migraine: current perspectives.
    Giamberardino MA; Affaitati G; Curto M; Negro A; Costantini R; Martelletti P
    Intern Emerg Med; 2016 Dec; 11(8):1045-1057. PubMed ID: 27339365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic antibodies against CGRP or its receptor.
    Bigal ME; Walter S; Rapoport AM
    Br J Clin Pharmacol; 2015 Jun; 79(6):886-95. PubMed ID: 25614243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: A systematic review and meta-analysis of randomized controlled trials.
    Robblee J; Hakim SM; Reynolds JM; Monteith TS; Zhang N; Barad M
    Headache; 2024 May; 64(5):547-572. PubMed ID: 38634515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.